Generic Name and Formulations:
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
CSL Behring, LLC
Indications for HAEGARDA:
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Adults and Children:
Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). 60 IU/kg twice weekly (every 3 or 4 days).
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|